However, therapeutic resistance to ICIs including antibodies blocking programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathways are emerging, leading to treatment failure and progressive disease in HCC patients (130). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.